A protein produced by specific cells in the brain has been shown to repair damaged brain networks. This discovery could allow a genetically engineered treatment for neurogenerative disorders such as Alzheimer’s. A key hallmark of neurogenerative diseases is the decay of the connections between neurons in the brain. If these connections could be restored it […]
A new high-throughput sequencing technique created by scientists at the University of Chicago will uncover how naturally occurring microbiomes respond to real-world conditions and diets. The technique, outlined in Nature Communications, directly analyses transfer RNA (tRNA) to give a clear picture of microbial communities’ reactions to environment changes including temperature variations and nutrient availability.
Researchers in Spain have specified the role that the protein PIF1, which can undo different structures in these molecules, plays in the human body. The study found that PIF1 contains the material to allow cells to function properly, and that improperly-repaired damage to the protein can cause problems for health.
A new method makes it possible to systematically identify specialised proteins that unpack DNA inside the nucleus of a cell, making the usually dense DNA more accessible for gene expression and other functions.
Computational researchers have developed a computer program which has revealed a previously unknown combination of drugs that may be the answer to triple-negative breast cancer.
A new method can examine protein assembly in real time, in living cells, to find problems in the process and diagnose the resulting diseases, according to new research.
Chemists have devised a way to rapidly synthesize and screen millions of novel proteins that could be used as drugs against Ebola and other viruses.
Researchers at Oregon State University have developed a great new RNA annotation tool.
Deep learning computers in a diagnostic imaging lab routinely defeat their human counterparts in diagnosing heart failure, detecting various cancers and predicting their strength.
AI genomics company Freenome has announced a partnership with proteomics company Biognosys, to enhance its broad-signal approach to early-cancer detection and precision oncology.